GVK - Gemeinsamer Verbundkatalog

Kopiebestellung | Speichern/Drucken | Merken

Ihre Aktion

suchen [und]

([PPN] Pica-Produktionsnummer)

1773221892

| 1 Treffer

	PPN:	1773221892
	Titel:	Accelerating the development of new drugs and diagnostics : maximizing the impact of the cures acceleration network / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies
	Sonst. Personen:	Olson, Steve 1956- [MitwirkendeR] ; Claiborne, Anne B. [MitwirkendeR]
	Körperschaft/en:	Institute of Medicine (U.S.). / Forum on Drug Discovery, Development, and Translation. [MitwirkendeR]
	Ort/Jahr:	Washington, D.C. : National Academies Press, c2012
	Sprache/n:	Englisch
	Umfang:	1 online resource (1 PDF file (xv, 115 p.))
	Anmerkung:	Includes bibliographical references
	ISBN:	978-0-309-26116-6 0-309-26116-3
	Schlagwörter:	*Drug Discovery / ; Diagnostic Techniques and Procedures / ; Congress /
	Inhalt:	This public workshop considered options and opportunities to maximize the usefulness and impact of the Cures Acceleration Network (CAN) program in order to advance translational sciences. The workshop objectives were to:1. Identify and catalog potential tools, methods, and approaches that hold promise for accelerating translational science.-- Consideration of such promising approaches will draw from the experiences of existing activities at other federal agencies related to the goals of CAN--for example, FDA, the U.S. Centers for Disease Control and Prevention (CDC), and the Agency for Healthcare Research and Quality (AHRQ).2. Discuss the authorities conferred to CAN and identify strategies for effectively using those authorities.-- Consideration of the CAN authorities will specifically explore the flexible research, or "other transaction," authority and will reference existing efforts in which such authority is currently applied across other federal agencies--for example, DARPA, the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).3. Explore promising models for public-private collaborations that could be strengthened or facilitated by activities under CAN.-- Discuss barriers to such collaborations and identify opportunities and potential solutions for moving past the identified barriers.-- Discuss the respective roles of multiple sectors, including, for example, the pharmaceutical and biotechnology industries, venture capital and private equity, and patient advocacy groups.4. Identify barriers and potential solutions to facilitate coordination of activities under CAN with the FDA regulatory review process and timelines.
	Links zum Titel:	https://www.ncbi.nlm.nih.gov/books/NBK100139/ (Teilweise kostenfrei zugänglich)
	Produktsigel:	ZDB-193-NCB

Besitzende Bibliothek(en): Klicken Sie auf einen Bibliotheksnamen oder auf > Detailansicht

Bitte beachten Sie, dass nicht immer alle Materialien tatsächlich für die Ausleihe zur Verfügung stehen. Weitere Informationen erhalten Sie über den Katalog der jeweiligen Bibliothek durch Klick auf OPC.
subito Lieferbibliotheken sind in Rot dargestellt